Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
804,525
-
Total 13F shares
-
132,993
-
Share change
-
+132,993
-
Total reported value
-
$876,125
-
Price per share
-
$6.58
-
Number of holders
-
8
-
Value change
-
+$876,125
-
Number of buys
-
8
Institutional Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q3 2022
As of 30 Sep 2022,
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) was held by
8 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
132,993 shares.
The largest 8 holders included
ARMISTICE CAPITAL, LLC, SABBY MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, BANK OF AMERICA CORP /DE/, UBS Group AG, Tower Research Capital LLC (TRC), MORGAN STANLEY, and Federation des caisses Desjardins du Quebec.
This page lists
8
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.